Myomo to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MYO(MYO) BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace
Myomo Reports Second Quarter 2025 Financial and Operating Results
MYOBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025. Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated): Rev
Myomo to Report Second Quarter 2025 Financial Results on August 11
MYOBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer question
Myomo Provides Highlights of Today’s Investor & Analyst Day Event
MYOBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company’s business model, provide a tour of its new headquarters and manufacturing facility and discuss l
Ascendiant Capital Maintains Buy on Myomo, Raises Price Target to $11.5
MYOCraig-Hallum Maintains Buy on Myomo, Lowers Price Target to $10
MYOCORRECTION: Myomo Q1 EPS $(0.08) Misses $(0.06) Estimate, Sales $9.83M Miss $10.91M Estimate
MYOMyomo Affirms FY2025 Sales Guidance of $50.00M-$53.00M vs $61.78M Est
MYOMyomo Sees Q2 Sales $9.000M-$9.500M vs $13.60M Est
MYOMyomo Q1 EPS $(0.80) Misses $(0.06) Estimate, Sales $9.83M Miss $10.91M Estimate
MYOA Glimpse of Myomo's Earnings Potential
MYOAscendiant Capital Maintains Buy on Myomo, Raises Price Target to $11
MYOHC Wainwright & Co. Maintains Buy on Myomo, Raises Price Target to $9.5
MYOCraig-Hallum Maintains Buy on Myomo, Raises Price Target to $11
MYOMyomo Q4 2024 Adj EPS $(0.01) Beats $(0.02) Estimate, Sales $12.10M Beat $9.90M Estimate
MYOMyomo Q3 2024 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $9.208M Beat $8.110M Estimate
MYOMyomo Raises FY2024 Sales Guidance from $28.00M-30.00M to $30.00M-31.00M VS Est.29.18M
MYOMyomo expects Q4 Sales Guidance of $9.50M-10.50M VS Est.9.8M
MYOMyomo Announces It Has Entered Into The First Contracts That Will Allow MyoPro To Be Provided To Patients Covered By Private Insurance On An In-Network Basis
MYO